Project Grant R21CA312903
- Federal Project Grant Award Summary The National Cancer Institute awarded a $382,449 Project Grant to the University of California, Los Angeles under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on July 16, 2025, with completion targeted for June 30, 2027. This research project develops and validates advanced dual-nuclei magnetic resonance imaging (MRI) techniques to non-invasively differentiate between recurrent brain metastases (RBM) and radiation-induced necrosis (RN)...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $414,402 Project Grant to The Regents of the University of California, San Francisco under the Cancer Treatment Research program (CFDA 93.395) for the period May 1, 2026 through April 30, 2028. This research project develops multi-modality imaging and biomarker integration methods to improve glioblastoma radiation therapy targeting. The deliverables include: (1) white matter infiltrative risk maps derived from diffusion...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of California, Los Angeles a $404,972 Project Grant effective August 1, 2025, through July 31, 2027, under the Cancer Treatment Research program (CFDA 93.395). This award supports fundamental and applied research investigating mechanisms of radiopharmaceutical therapy (RPT) resistance in metastatic castration-resistant prostate cancer. The research will evaluate how the ectonucleotidase enzyme ENPP1...
- Federal Grant Award Summary The University of California, San Francisco (UCSF) received a $729,587 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded August 21, 2025, with completion targeted for July 31, 2030. The project aims to develop a personalized, voxel-wise predictive model for identifying brain metastases risk in non-small cell lung cancer adenocarcinoma patients using multi-parametric magnetic resonance imaging. The...
- Federal Grant Award Summary The National Cancer Institute awarded The Leland Stanford Junior University a $584,521 Project Grant on August 8, 2025, under the Cancer Treatment Research program (CFDA 93.395) to investigate subclonal determinants of radiation response in soft tissue sarcomas. The research will deliver three primary products: (1) identification and validation of epigenetic changes, including DNA methylation and chromatin accessibility alterations, that confer radioresistance to...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded a Project Grant totaling $209,910 to the University of California, San Francisco (UCSF), effective August 1, 2025, through July 31, 2027, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). This award supports mechanistic and functional genomic interrogation of meningioma radiotherapy response genes. The research builds upon...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Regents of the University of California, San Francisco a $700,838 Project Grant under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) beginning April 1, 2026 and concluding March 31, 2031. This award supports the development and optimization of advanced magnetic resonance (MR) imaging and treatment planning methodologies to enable functional avoidance stereotactic body radiation therapy (FA-SBRT) for...
- Federal Project Grant Award Summary The National Cancer Institute, under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded the University of California, Los Angeles $825,627 beginning May 1, 2026, to develop advanced machine learning models for improving breast cancer prognosis prediction. The project, titled "Vision-Language Models with Explainability for Breast Cancer Prognosis Using Image and Clinical Data," will deliver three primary research products: (1)...
- Federal Grant Award Summary The National Cancer Institute awarded a $528,265 Project Grant to the University of California, Los Angeles (UCLA) on May 7, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support fragment-based drug discovery against oncogenic microRNA (oncomir) precursors. The research utilizes high-throughput crystallographic screening at the National Synchrotron Light Source II to identify and characterize small-molecule inhibitors targeting three prominent...
- Federal Project Grant Award Summary The University of California, Los Angeles received a $640,956 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded on May 15, 2026, with a completion date of April 30, 2031. This grant supports the development of an artificial intelligence-enhanced perfusion magnetic resonance imaging (MRI) tool designed to optimize yttrium-90 (Y90) microsphere distribution in radioembolization...
The National Cancer Institute (NCI), under its Cancer Treatment Research program (CFDA 93.395), awarded a $368,156 Project Grant to the University of California, Los Angeles (UCLA) for a two-year research initiative (June 1, 2026 – May 31, 2028). The award funds research investigating radiation-induced cognitive impairment in cancer patients undergoing cranial radiotherapy. UCLA will conduct mechanistic studies using human induced pluripotent stem cell (iPSC)-derived cortical organoids to elucidate how radiation exposure disrupts neural lineage commitment and drives aberrant transdifferentiation of neural stem/progenitor cells into endothelial-like phenotypes, which is hypothesized to contribute to long-term cognitive decline in survivors. The research deliverables include comprehensive characterization of radiation-induced cellular lineage transitions using single-cell and spatial transcriptomic approaches, followed by functional assessments of neural network activity through calcium imaging and multielectrode array recordings. The study will evaluate potential mitigation strategies through targeted inhibition of endothelial-inductive pathways (VEGF, FGFR, NOTCH) using existing pharmacologic inhibitors. Given the translational potential of targeting clinically available pathway inhibitors, this R21 mechanism research is designed to address a significant gap in understanding cellular mechanisms underlying radiation-induced neurotoxicity and inform future neuroprotective interventions for cancer patients.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $368.2k | 5/15/26 |